Risk factors, prognostic factors, and nomograms for bone metastasis in patients with newly diagnosed infiltrating duct carcinoma of the breast: a population-based study

Table 1 Clinical and pathological features of patients newly diagnosed as infiltrating duct carcinoma of breast

Variables	SEER (N = 141,959)	Percent
Ag
22–54	49,438	34.83
55–79	81,114	57.14
≥ 80	11,407	8.03
Race
White	113,888	80.23
Black	14,466	10.19
Other	13,605	9.58
Sex
Female	140,883	99.24
Male	1076	0.76
Primary Site
Nipple	479	0.34
Central portion of breast	7319	5.16
Upper-inner quadrant of breast	20,520	14.45
Lower-inner quadrant of breast	9267	6.53
Upper-outer quadrant of breast	55,426	39.04
Lower-outer quadrant of breast	12,097	8.52
Axillary tail of breast	736	0.52
Overlapping lesion of breast	36,115	25.44
Grade
I	31,092	21.90
II	59,639	42.01
III	50,920	35.87
IV	308	0.22
Laterality
Left - origin of primary	71,742	50.54
Right - origin of primary	70,217	49.46
T stage
T1	90,286	63.60
T2	42,097	29.65
T3	6131	4.32
T4	3445	2.43
N stage
N0	99,074	69.79
N1	32,876	23.16
N2	6570	4.63
N3	3439	2.42
Radiotherapy
No	61,535	43.35
Yes	80,424	56.65
Chemotherapy
No	80,128	56.44
Yes	61,831	43.56
Surgery
No	5465	3.85
Yes	136,494	96.15
Brain metastasis
No	141,757	99.86
Yes	202	0.14
Liver metastasis
No	140,980	99.31
Yes	979	0.69
Lung metastasis
No	140,826	99.20
Yes	1133	0.80
Breast subtype
HR−/HER2-	17,731	12.49
VHR−/HER2+	6900	4.86
HR+/HER2-	100,919	71.09
HR+/HER2+	16,409	11.56
ER status
Negative	26,250	18.49
Positive	115,709	81.51
PR status
Negative	40,088	28.24
Positive	101,871	71.76
HER2 status
Negative	118,650	83.58
Positive	23,309	16.42
Insurance
Uninsured	2701	1.90
Insured	139,258	98.10
Marital status
Unmarried	53,130	37.43
Married	88,829	62.57

ISSN: 1471-2407